Carisma Therapeutics, Inc.
CARM
$0.2153
$0.00180.84%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 7.92% | -63.19% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 7.92% | -63.19% | |||
| Cost of Revenue | 37.54% | -26.01% | |||
| Gross Profit | -50.17% | -29.97% | |||
| SG&A Expenses | -24.47% | -6.42% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 18.02% | -20.79% | |||
| Operating Income | -20.63% | -12.63% | |||
| Income Before Tax | -38.84% | -13.80% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -38.84% | -13.80% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -38.84% | -13.80% | |||
| EBIT | -20.63% | -12.63% | |||
| EBITDA | -22.40% | -8.69% | |||
| EPS Basic | -38.31% | -13.66% | |||
| Normalized Basic EPS | -22.58% | -13.70% | |||
| EPS Diluted | -38.31% | -13.66% | |||
| Normalized Diluted EPS | -22.58% | -13.70% | |||
| Average Basic Shares Outstanding | 0.40% | 0.11% | |||
| Average Diluted Shares Outstanding | 0.40% | 0.11% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||